In a banner year for venture capital finance, biotechnology has garnered a significant portion of total funding and has enjoyed a record year as an industry. This record level of venture capital funding was, in part, due to renewed interest in life sciences due to the COVID-19 pandemic, but was also the result of the industry’s continued maturation. biotechnology and the opening of the IPO window for pre-revenue biotechnology. businesses and other start-ups. The increased funding was also the result of the biotech industry’s greater success in developing and bringing to market new therapies that meet the promises the industry showed in the early 1990s and beyond. Exciting times to be involved in this industry!
Pharma & Biotech’s good results supported a record year for life sciences due to investor interest in vaccines, antivirals and companies engaged in the fight against COVID-19. $ 36 billion of capital was invested in life science companies in 2020, 41% more than the previous annual record of $ 26 billion invested in 2018. Investments in drug discovery have nearly doubled from from $ 8.8 billion in 2019 to $ 16.2 billion in 2020.